EurekaMag.com logo
+ Site Statistics
References:
52,725,316
Abstracts:
28,411,598
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Anti-TNFa therapy of rheumatoid arthritis: what have we learned?


Annual Review of Immunology 001: 3-96
Anti-TNFa therapy of rheumatoid arthritis: what have we learned?
Rheumatoid arthritis (RA), a systemic disease, is characterized by a chronic inflammatory reaction in the synovium of joints and is associated with degeneration of cartilage and erosion of juxta-articular bone. Many pro-inflammatory cytokines including TNFa, chemokines, and growth factors are expressed in diseased joints. The rationale that TNFa played a central role in regulating these molecules, and their pathophysiological potential, was initially provided by the demonstration that anti-TNFa antibodies added to in vitro cultures of a representative population of cells derived from diseased joints inhibited the spontaneous production of IL-1 and other pro-inflammatory cytokines. Systemic administration of anti-TNFa antibody or sTNFR fusion protein to mouse models of RA was shown to be anti-inflammatory and joint protective. Clinical investigations in which the activity of TNFa in RA patients was blocked with intravenously administered infliximab, a chimeric anti-TNFa monoclonal antibody (mAB), has provided evidence that TNF regulates IL-6, IL-8, MCP-1, and VEGF production, recruitment of immune and inflammatory cells into joints, angiogenesis, and reduction of blood levels of matrix metalloproteinases-1 and -3. Randomized, placebo-controlled, multi-center clinical trials of human TNFa inhibitors have demonstrated their consistent and remarkable efficacy in controlling signs and symptoms, with a favorable safety profile, in approximately two thirds of patients for up to 2 years, and their ability to retard joint damage. Infliximab (a mAB), and etanercept (a sTNF-R-Fc fusion protein) have been approved by regulatory authorities in the United States and Europe for treating RA, and they represent a significant new addition to available therapeutic options. Reprinted by permission of the publisher.


Accession: 009770095



Related references

Loss of expansion of CD94/NKG2a expressing T cells may predict disease relapse in patients with rheumatoid arthritis (RA) following withdrawal of anti-tumour necrosis factor-alpha(anti-TNFA) therapy. 2007

Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?. Annual Review of Immunology 19: 163-196, 2001

Necrotic ulcerations of cutaneous vasculitis in rheumatoid arthritis: treatment with anti-TNFa. Annales de Dermatologie et de Venereologie 133(5, Part 1): 453-455, 2006

Safety of rituximab in the routine treatment of rheumatoid arthritis in Italy in patients refractory to anti-TNFa drugs: results from the observational retrospective-prospective RUBINO study. Reumatismo 66(3): 224-232, 2016

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. New England Journal of Medicine 343(22): 1594-1602, 2000

Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement. Annals of the Rheumatic Diseases 63(10): 1218-1221, 2004

Predictors for the 5-year risk of serious infections in patients with rheumatoid arthritis treated with anti-tumour necrosis factor therapy: a cohort study in the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. Rheumatology 52(6): 1052-1057, 2013

What Have We Learned about the Pathogenesis of Rheumatoid Arthritis from TNF-Targeted Therapy?. 2012

Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis and Rheumatism 52(4): 1020-1030, 2005

Anti-CCP2 is an adjunct to, not a surrogate for, rheumatoid factor in the diagnosis of rheumatoid arthritis: diagnostic utility of anti-CCP2 antibodies in Egyptian patients with rheumatoid arthritis. Scandinavian Journal of Rheumatology 37(5): 329-336, 2008